PF-07832837 is under clinical development by Pfizer and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 74% phase transition success rate (PTSR) indication ...
VI-0810 is under development for the treatment of diabetes. Vivus, a subsidiary of Icahn Enterprises LP, is developing drugs for the treatment of exocrine pancreatic insufficiency, obesity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback